UNSPSC 51172477: Nux vomica/pancreatin/papain/pepsin/phenobarbital/sodium bicarbonate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.

UNSPSC 51172477 Nux vomica/pancreatin/papain/pepsin/phenobarbital/sodium bicarbonate is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The one recent opportunity in the dataset—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—concerns immunoassay screening, LC/MS/MS or GC/MS confirmation, and alternative testing methodologies (oral fluid and hair testing), not the pharmaceutical compounds named in the code. The scope requires lab certification from SAMHSA, TX DPS, or CAP and includes staffing two collection sites in Plano and McKinney plus operation of an Interactive Voice Response system for randomized testing notifications. This is a drug-testing services procurement, not the sale of gastrointestinal or anthelmintic pharmaceutical formulations the code's name suggests.

Collin County's RFP 2026-327, posted September 25, 2026, seeks proposals by July 23, 2026 at 2:00 p.m. for approximately 25,031 annual tests (5,452 five-panel screens, 18,006 six-panel screens, and ancillary testing) across a two-year initial contract term with three optional one-year renewals not to exceed five years total. The estimated contract value is $600,000. Pricing must be submitted on a per-test basis across three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives), with all costs including freight, delivery, insurance, and staffing; price redetermination is capped at 3.0 percent annually aligned to medical Consumer Price Index increases. Evaluation weighs vendor understanding (30 points), firm qualifications (25 points), client references (15 points), cost (30 points), and optional Phase 2 demonstrations and interviews (up to 30 points). The anticipated award date is August 10, 2026. The code shows little relevant recent activity; the single tagged opportunity appears to reflect a data-entry or classification error rather than genuine pharmaceutical procurement under this code.